One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

References

• MillerNHCompliance with treatment regimens in chronic asymptomatic diseasesAm J Med199710243499217586
   PubMedGoogle Scholar
• Rodriguez-RosadoRJimenez-NacherISorianoVVirological failure and adherence to antiretroviral therapy in HIV-infected patientsAIDS199812111211139662214
   PubMed Web of Science ®Google Scholar
• BangsbergDRCharleboisEDGrantRMHigh levels of adherence do not prevent accumulation of HIV drug resistance mutationsAIDS2003171925193212960825
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med2000133213010877736
   PubMed Web of Science ®Google Scholar
• MaggioloFRavasioLRipamontiDSimilar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitorsClin Infect Dis20054015816315614706
   PubMed Web of Science ®Google Scholar
• BangsbergDLess than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppressionClin Infect Dis20064393994116941380
   PubMed Web of Science ®Google Scholar
• ShahBWalsheLSapleDGAdherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, IndiaClin Infect Dis2007441235124417407045
   PubMed Web of Science ®Google Scholar
• MaggioloFAiroldiMKleinloogHDEffect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patientsHIV Clin Trials2007828229217956829
   PubMed Web of Science ®Google Scholar
• BangsbergDRAcostaEPGuptaRAdherence-resistance relationship for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessAIDS20062022323116511415
   PubMed Web of Science ®Google Scholar
• BangsbergDRPorcoTCKagayCModelling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimatesJ Infect Dis200419016216515195256
   PubMed Web of Science ®Google Scholar
• KleebergerCAPhairJPStrathdeeSADeterminants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS Cohort StudyJ Acquir Immune Defic Syndr200126829211176272
   PubMed Web of Science ®Google Scholar
• GordilloVdel AmoJSorianoVSociodemographic and psycological variables influencing adherence to antiretroviral therapyJ Acquir Immune Defic Syndr19991317631769
   Google Scholar
• VervoortSCJMBorleffsJCCHoepelmanAIMAdherence in antiretroviral therapy: a review of qualitative studiesAIDS20072127128117255734
   PubMed Web of Science ®Google Scholar
• MaggioloFRipamontiDAriciCSimpler regimens may enhance adherence to antiretrovirals in HIV infected patientsHIV Clin Trials2002537137812407486
   PubMedGoogle Scholar
• TrottaMPAmmassariACozzi-LepriAAdherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than those receiving protease inhibitor-containing regimensAIDS2003171099110212700467
   PubMed Web of Science ®Google Scholar
• FlandrePPeytavinGMeifreddyVAdherence to antiretroviral therapy and outcomes in HIV infected patients enrolled in an induction/maintenance randomized trialAntivir Ther2002711312112212923
   PubMed Web of Science ®Google Scholar
• StoneVEJordanJTolsonJPerspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of Highly Active Antiretroviral Therapy (HAART) regimens in predicting adherenceJ Acquir Immune Defic Syndr20043680881615213564
   PubMed Web of Science ®Google Scholar
• BoyleBJayaweeraDWittMDRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials2008916417618547903
   PubMed Web of Science ®Google Scholar
• SinghNBermanSMSwindellsSAdherence of human immunodeficiency virus-infected patients to antiretroviral therapyClin Infect Dis19992982483010589897
   PubMed Web of Science ®Google Scholar
• HolmesWCBilkerWBWangHHIV/AIDS-specific quality of life and adherence to antiretroviral therapy over timeJ Acquir Immune Defic Syndr20074632332717846560
   PubMed Web of Science ®Google Scholar
• BensonCAvan der HorstCLaMarcaAA randomized study of emtricitabine and lamivudine in stably suppressed patients with HIVAIDS2004182269227615577539
   PubMed Web of Science ®Google Scholar
• McHorneyCAWareJEJrRaczekAEThe MOS 36-Item Short-Form Health Survey (SF-36) Psychometric and clinical tests of validity in measuring physical and mental health constructsMed Care1993312472638450681
   PubMed Web of Science ®Google Scholar
• SriwatanakulKKelvieWLasagnaLStudies with different types of visual analogue scales for measurement of painClin Pharmacol Ther1983342342396872418
   PubMed Web of Science ®Google Scholar
• GiordanoTPGuzmanDClarkRMeasuring adherence to antiretroviral therapy in a diverse population using a visual analogue scaleHIV Clin Trials20045747915116282
   PubMed Web of Science ®Google Scholar
• ClotetBCarmenaJPulidoFAdherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patientsHIV Clin Trials20045333915002085
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention1993 revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adultsMMWR199241912
   Google Scholar
• GlassTRDe GeestSWeberRCorrelates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort studyJ Acquir Immune Defic Syndr20064138539216540942
   PubMed Web of Science ®Google Scholar
• HaysRDWoolleyJMThe concept of clinically meaningful in health-related quality-of-life research. How meaningful is itPharmacoeconomics20001841942311151395
   PubMed Web of Science ®Google Scholar
• BissonGPRowhAWeinsteinRAntiretroviral failure despite high levels of adherence: discordant adherence-response relationship in BotswanaJ Acquir Immune Defic Syndr20084910711018667926
   PubMed Web of Science ®Google Scholar
• GolinCEEarpJTienHCA 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ARTJ Acquir Immune Defic Syndr200642425116763491
   PubMed Web of Science ®Google Scholar
• AmmassariAMurriRPezzottiPSelf-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infectionJ Acquir Immune Defic Syndr20012844544911744832
   PubMed Web of Science ®Google Scholar
• HeathKVSingerJO’ShaughnessyMVIntentional nonadherence due to adverse symptoms associated with antiretroviral therapyJ Acquir Immune Defic Syndr20023121121712394800
   PubMed Web of Science ®Google Scholar
• MannheimerSBWoldNGardnerEMMild-to moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individualsClin Infect Dis20084694194518279044
   PubMed Web of Science ®Google Scholar
• ShenLPetersonSSedaghatARDose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNat Med20081476276618552857
   PubMed Web of Science ®Google Scholar
• DeJesusEYoungBMorales-RamirezJOSimplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified anti-retroviral therapy in virologically suppressed HIV-1-infected patientsJ Acquir Immune Defic Syndr20095116317419357529
   PubMed Web of Science ®Google Scholar
• HolmesWCBilkerWBWangHHIV/AIDS-specific quality of life and adherence to antiretroviral therapy over timeJ Acquir Immune Defic Syndr20074632332717846560
   PubMed Web of Science ®Google Scholar